Semaglutide News and Research

Latest Semaglutide News and Research

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

Chinese study shows lasting weight loss after tirzepatide treatment

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

23 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025

GLP-1 receptor agonists linked to lower dementia risk in type 2 diabetes

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access journal BMJ Open Diabetes Research & Care.

22 Jul 2025

Extreme childhood obesity drives liver and diabetes risks

Extreme obesity in US youth has risen significantly, linked to higher rates of diabetes and liver complications, necessitating immediate public health action.

22 Jul 2025

Weight regain observed in patients after ending obesity drug treatment

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine.

22 Jul 2025

Muscle loss from GLP-1 drugs could undermine long-term health

Popular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in heart and lung function essential for long-term good health, University of Virginia experts warn in a new paper.

21 Jul 2025

GLP-1 weight-loss drugs are reshaping modern dating and intimacy

GLP-1 weight-loss drugs are changing how people date and connect. In a nationally representative survey of 2,000 single U.S. adults (ages 18 to 91) led by the Kinsey Institute at Indiana University with DatingNews.com, GLP-1 users reported a wide range of physical, social, and psychological shifts they attributed to the drug.

18 Jul 2025

Retrospective analyses indicate Ozempic’s protective effects against stroke fatality

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether.

18 Jul 2025

Gut-brain axis in eating disorders offers new treatment potential

Understanding the gut-brain axis is key to addressing eating disorders. This study highlights microbiota's influence and emerging therapeutic approaches.

16 Jul 2025

A million veterans gave DNA to aid health research. Scientists worry the data will be wasted.

One of the world's biggest genetic databases comprises DNA data donated over the years by more than a million retired military service members. It's part of a project run by the Department of Veterans Affairs.

16 Jul 2025

Extracellular vesicle RNA reveals clues about obesity and metabolic disease

Our study examines how RNA in extracellular vesicles (EVs) can provide insights into metabolic phenotypes related to obesity. By using functional genomics approaches, we found a high representation of genes and regulatory elements previously associated with obesity and type 2 diabetes represented by the RNA cargo within these EVs.

15 Jul 2025

Effective weight loss achieved even with inconsistent GLP-1 access

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, according to a study being presented by a private weight-loss company Monday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

15 Jul 2025

Weight loss drugs can boost testosterone in men with obesity or diabetes

Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

14 Jul 2025

New guideline recommends proper preconception care for women with diabetes

A joint guideline released today from the Endocrine Society and the European Society of Endocrinology (ESE) recommends women with diabetes receive proper preconception care and access to emerging diabetes technology and therapeutics to manage their blood sugar before, during and after pregnancy.

13 Jul 2025

Higher protein intake may help prevent muscle loss in semaglutide users

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Combining tirzepatide and hormone therapy boosts weight loss in postmenopausal women

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Tirzepatide reduces obesity-associated breast cancer growth in mouse model

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Innovative genome editing approach could be the key to lifelong effective weight management

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way for the body to make its own weight-loss drugs, doing away with injections in favor of a one-time treatment.

9 Jul 2025

New study identifies factors linked to successful weight loss using GLP-1RAs

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss after taking prescription drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (sold under the brand names Ozempic and Wegovy).

9 Jul 2025